ADVFN Logo ADVFN
市場データ
ニュース
投資ツール
市場
発見

Hot Features

Follow Feed

フォローフィードコミュニティでトレーダーや投資家とつながりましょう.

ライブオプションフロー

包括的なオプション データを調査し、オプション フローで高度なフィルターを使用します.

モニター

ターミナル モニターで株式と資産のウォッチリストを整理および監視します
サインイン Premium Iconプレミアム Help Menu
Bitcoin
98,974.38
-1.68%
S&P 500
6,040.53
-0.50%
Dow Jones
44,544.66
-0.75%
US Dollar vs Yen
155.195
-0.01%
Brent Oil
76.385
0.00%
Registration Strip Icon for monitor ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。
登録
  1. ホーム
  2. 投資
  3. 株式
  4. アメリカ
  5. NASDAQ
  6. Tyra Biosciences Inc (TYRA)

  7. Tyra Biosciences Inc (TYRA) ニュース

TYRA

Tyra Biosciences (TYRA)

Tyra Biosciences Inc
から:
次の項目別のソート:
 Showing the most relevant articles for your search:NASDAQ:TYRA
日付受信時刻ニュースソース見出しコード企業名
2025/01/3006 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
2025/01/3006 : 05PR Newswire (US)Tyra Biosciences Announces Appointment of Adele Gulfo to Board of DirectorsNASDAQ:TYRATyra Biosciences Inc
2025/01/2308 : 00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2025/01/2222 : 00PR Newswire (US)Tyra Biosciences Announces Poster Presentations at 2025 ASCO Gastrointestinal Cancers SymposiumNASDAQ:TYRATyra Biosciences Inc
2025/01/1022 : 00PR Newswire (US)Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Non-Muscle Invasive Bladder Cancer (SURF302)NASDAQ:TYRATyra Biosciences Inc
2024/12/1007 : 42Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/12/0711 : 30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
2024/12/0711 : 30Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
2024/12/0606 : 21Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/12/0309 : 06Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/11/2106 : 29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/11/2011 : 31Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
2024/11/1507 : 52Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/11/1406 : 05PR Newswire (US)Tyra Biosciences to Present at Upcoming Investor ConferencesNASDAQ:TYRATyra Biosciences Inc
2024/11/0806 : 05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
2024/11/0806 : 05PR Newswire (US)Tyra Biosciences Reports Third Quarter 2024 Financial Results and HighlightsNASDAQ:TYRATyra Biosciences Inc
2024/10/3105 : 01Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/10/2906 : 15Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/10/2820 : 00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
2024/10/2820 : 00PR Newswire (US)Tyra Biosciences Receives IND Clearance from FDA to Proceed with Phase 2 Study of TYRA-300 in Pediatric Achondroplasia (BEACH301)NASDAQ:TYRATyra Biosciences Inc
2024/10/2521 : 01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
2024/10/2507 : 21PR Newswire (US)Tyra Biosciences Reports Interim Clinical Proof-of-Concept Data for TYRA-300, an Investigational Oral FGFR3-Selective Inhibitor, in Phase 1/2 SURF301 Study in Patients with Metastatic Urothelial Cancer (mUC)NASDAQ:TYRATyra Biosciences Inc
2024/10/2405 : 05PR Newswire (US)Tyra Biosciences to Host Conference Call on Interim Clinical Data of TYRA-300 from SURF301 Phase 1/2 Study on October 25, 2024, at 8am ETNASDAQ:TYRATyra Biosciences Inc
2024/10/2310 : 15Edgar (US Regulatory)Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]NASDAQ:TYRATyra Biosciences Inc
2024/10/2309 : 49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/10/2309 : 47Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/10/1905 : 23Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TYRATyra Biosciences Inc
2024/10/1121 : 00PR Newswire (US)Tyra Biosciences Announces Late-Breaking Oral Presentation on Preliminary Safety and Anti-Tumor Activity of TYRA-300 from SURF301 at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2024)NASDAQ:TYRATyra Biosciences Inc
2024/09/1905 : 05Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
2024/09/1904 : 59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TYRATyra Biosciences Inc
 Showing the most relevant articles for your search:NASDAQ:TYRA

最近閲覧した銘柄

COIN
ADAUSD
Cardano
USOTC
RHHBY
Roche (QX)
NASDAQ
MSFT
Microsoft
NASDAQ
GOOGL
Alphabet
NASDAQ
NVDA
NVIDIA
FX
USDJPY
US Dollar vs Yen
USOTC
BASFY
BASF (QX)
NYSE
VZ
Verizon Communications
COIN
BTCUSD
Bitcoin
NYSE
MCD
McDonalds
NASDAQ
AMZN
Amazon.com
AMEX
SPY
SPDR S&P 500
NASDAQ
AAPL
Apple
PM
XAUUSD
Gold vs US Dollar
NYSE
XOM
Exxon Mobil
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

日本
会社情報
ビジネス
人気
アプリを入手
App Store
Google Play

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

© 2025 ADVFN PLC - 全著作権所有

広告を削除する

サインアップして広告なしのエクスペリエンスを体験してください

広告なし

今すぐ試してください

広告を残す